Neurotoxicity
5
Pipeline Programs
2
Companies
4
Clinical Trials
1
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
3
2
Early DiscoveryClinical DevelopmentMarket
On Market (1)
Approved therapies currently available
U
DULOXETINE HYDROCHLORIDEApproved
duloxetine hydrochloride
Unknown Companyoral2018
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Alliance PharmaceuticalsUK - Wiltshire
3 programs3
duloxetine hydrochloridePhase 31 trial
gabapentinPhase 31 trial
lamotriginePhase 31 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Veloxis PharmaceuticalsEnvarsus
Alliance Pharmaceuticalsduloxetine hydrochloride
Alliance Pharmaceuticalslamotrigine
Alliance Pharmaceuticalsgabapentin
Clinical Trials (4)
Total enrollment: 462 patients across 4 trials
Envarsus Neurotoxicity Burden in Liver Transplant Patients
Start: Jan 2020Est. completion: Jan 2024
Phase 4Completed
Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
Start: Apr 2008Est. completion: Mar 2013231 patients
Phase 3Completed
Lamotrigine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
Start: Feb 2004Est. completion: Nov 2013131 patients
Phase 3Completed
Gabapentin in Treating Peripheral Neuropathy in Cancer Patients Undergoing Chemotherapy
Start: Feb 2002Est. completion: Nov 2007100 patients
Phase 3Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space